The Shanghai Municipal People's Government recently announced the winners of the fifth Shanghai Intellectual Property Innovation Awards. The awards honor organizations that excel in creating, protecting, and commercializing intellectual property (IP).
Awards were presented on Oct 18 at the 22nd Shanghai International Intellectual Property Forum. ShanghaiTech University's Office of Technology Transfer stood out for building a full‑cycle ecosystem for science commercialization.
Founded in 2019, the office combines university, industry, capital, and government resources to enable efficient IP utilization and value creation, fueling a robust innovation pipeline from research to market.
The office has achieved remarkable results. Annual patent licensing rates have reached 25 percent, while PCT and overseas patents account for 30 percent.
Since 2018, patent licensing contracts have exceeded 7 billion yuan ($985 million), making ShanghaiTech University one of China's top universities for six consecutive years. Between 2022 and 2024, it received 26 awards, including honors for high-value patent operations.
Key projects have made significant advances. In 2022, HJM353 (EED inhibitor) obtained clinical trial approvals in China and the US. Licenses for GT919 and GT929 capsules were issued in 2022–23. The CS101 injection completed phase I, and a Dago Biotech compound received US FDA trial approval in January 2025.
Embedding IP operations into its innovation ecosystem can drive entrepreneurship and innovation, creating a complete pathway from lab research to market impact and reinforcing Shanghai as a strong IP city.
